Xenon Pharmaceuticals Inc. (XENE) Stock Price & Analysis

Xenon Pharmaceuticals Inc. (XENE) closed at USD 37.54 on Thursday, October 29, 2026, up 3.30% on the day. The US market is currently closed (after-hours); this is not a live price.

The prior close was USD 36.34; the Oct 29, 2026 session ranged USD 36.49–37.69 on volume of 1,543,675 shares. Market capitalization is $3.64B, with a 52-week range of USD 33.38–72.66 (NGM). Source: Nexqual, retrieved October 29, 2026 at 21:18 UTC.

Also available as compact Markdown for AI agents: nexqual.com/XENE.md

Key facts (XENE)

• Last four reported quarters (through Jun 30, 2026): revenue $0K, net income -$409M, free cash flow -$339M (SEC filings).
• Insider open-market sales, last ~7 months: 4 Form 4 filings, $1.2M; 1 not under a Rule 10b5-1 plan ($641K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Insider open-market purchases, last ~7 months: 2 Form 4 filings, $1.7M; 0 by opportunistic insiders, 0 by routine insiders.
• Analysts: Buy (mean 1.89 on a 1–5 scale) (19 analysts), mean target USD 71.94 (range 46–90).
• Total return with dividends: 1Y -12.0% vs S&P 500 +14.4%; 5Y +20.5% vs S&P 500 +79.1%.
• Next earnings: 2026-11-02, EPS estimate USD -1.15, revenue estimate $0K.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (XENE)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (XENE)

P/B 2.9x · FCF yield -9.31% · Earnings yield -11.26%

Insider sales (SEC Form 4, open-market, last ~7 months) (XENE)

3 of 4 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Insider purchases (SEC Form 4, open-market, last ~7 months) (XENE)

2 purchases, $1.7M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.

Analysts (XENE)

Consensus Buy (mean 1.89 on a 1–5 scale), 19 analysts; mean target USD 71.94 (low 46, high 90).

Rating changes, last 120 days:

Total return (dividends reinvested) (XENE)

XENE earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

XENE recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

XENE suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 26, 2026.

Companies that name XENE in their SEC reports

XENE company outlook (results filed Aug 6, 2026)

• “X-TOLE3 enrollment outside of Japan is expected to complete in 2026. • The Phase 3 X-ACKT study of azetukalner in PGTCS continues to enroll and is intended to support regulatory submissions for an additional epilepsy indication.”
• “Neuropsychiatry Programs • Enrollment is ongoing in the Phase 3 X-NOVA2 and X-NOVA3 studies evaluating azetukalner in patients with MDD, with topline data from X-NOVA2 expected in H1 2027. • Enrollment is ongoing in the Phase 3 X-CEED study evaluating azetukalner in patients with BPD I or II.”
• “Study completion is expected in H2 2026 to support initiating a Phase 2 proof-of-concept study in acute pain. • Xenon recently received approval of its Clinical Trial Application (CTA) to initiate a Phase 1 study of XEN1720 targeting Na V 1.7.”
• “Study completion is expected in H2 2026 to support initiating a Phase 2 proof-of-concept study in acute pain.”

Quoted word-for-word from the SEC 8-K results press release.

XENE analyst estimates and revisions

XENE options: expected move

Options price a move of about ±8.1% (±$3.00) by Nov 20, 2026, which includes earnings on Nov 2, 2026. Over the last 8 reports the stock moved ±6% on average.

30-day implied volatility 46% vs 113.6% realized over the last 30 trading days. Put/call ratio (volume) 0.09. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 29, 2026 at 21:18 UTC)

Technical Analysis (XENE)

Nexqual's technical model rates XENE "SELL" based on 2 bullish and 4 bearish signals across 127 daily candles, as of October 29, 2026 at 21:18 UTC.

Analyst Ratings (XENE)

Wall Street analysts rate XENE "Buy" based on 19 analysts, with a mean price target of USD 71.94 (range USD 46–90), per Nexqual as of October 29, 2026 at 21:18 UTC.

Earnings (XENE)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 21:18 UTC.

Financials & Fundamentals (XENE)

Source: Nexqual, October 29, 2026 at 21:18 UTC.

Financial Health Score (XENE)

Nexqual rates Xenon Pharmaceuticals Inc.'s overall financial health "Weak" across five dimensions, as of October 29, 2026 at 21:18 UTC.

Ownership (XENE)

Source: Nexqual, October 29, 2026 at 21:18 UTC.

Leadership (XENE)

Xenon Pharmaceuticals Inc. is led by Ian C. Mortimer C.M.A., President, CEO & Director, per Nexqual as of October 29, 2026 at 21:18 UTC.

Major Backers & Investors (XENE)

Notable institutional backers of Xenon Pharmaceuticals Inc. include FMR, LLC, Avoro Capital Advisors LLC, Fidelity, according to Nexqual as of October 29, 2026 at 21:18 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 21:18 UTC.

From Xenon Pharmaceuticals Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• If one or more of our proprietary or partnered product candidates is approved for the treatment of epilepsy, we anticipate that they could potentially compete with other anti-seizure medications, or ASMs, or one another.
• If one or more of our proprietary product candidates were approved for the treatment of MDD, we anticipate that they could potentially compete with other anti-depressant medications, or ADs.

Partnerships

• Pursuant to our collaboration with Neurocrine Biosciences, Neurocrine Biosciences controls the prosecution, maintenance and other matters relating to some of the patent portfolio for the selective Nav1.6 inhibitors and dual Nav1.2/1.6 inhibitors subject thereto, although we have a right to comment.
• In September 2018, we signed an agreement with Bausch Health to buy out all future milestone payments and royalties owed to Bausch Health with respect to azetukalner, including up to $39.6 million in potential clinical development, regulatory and sales-based milestones and a mid-to-high single digit percentage royalty on commercial sales in exchange for a one-time payment of $6.0 million.

Legal & Regulatory Risks (Item 1A, quoted)

• We have no marketed proprietary products and are advancing clinical development through Phase 3 clinical studies for our azetukalner program in epilepsy, major depressive disorder, and bipolar depression. These studies may not result in regulatory approval or successful commercialization of our product candidates.
• We are subject to evolving global laws and regulations relating to privacy, data protection and information security, which may require us to incur substantial compliance costs, and any failure or perceived failure by us to comply with such laws and regulations may harm our business and operations.
• Our business substantially depends upon the successful development of azetukalner. If we are unable to obtain regulatory approval for, and successfully commercialize, azetukalner, our business may be materially harmed.
• The regulatory approval processes of the FDA, EMA and regulators in other foreign jurisdictions are lengthy, time-consuming and inherently unpredictable. If we, or our collaborators, are unable to obtain regulatory approval for our product candidates in a timely manner, or at all, our business may be substantially harmed.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 21:18 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt